fbpx

Cure Parkinson’s

18 results.

October 11, 2018 ICYMI: Three big takeaways from Grand Challenges in Parkinson’s Disease

Did you miss Grand Challenges in Parkinson’s Disease and Rallying to the Challenge? Don’t worry. We have you covered. Just over a week ago, the…

VAI DEFAULT HEADER
September 25, 2017 Van Andel Research Institute hosts unique symposium on Parkinson’s disease

Grand Rapids, Mich. (Sept. 25, 2017)—Leading Parkinson’s experts and advocates from around the world will gather at Van Andel Research Institute in…

August 31, 2017 Taking on the challenge: Parkinson’s disease events to foster collaboration, pursuit of a cure

In less than a month, scientists, physicians and people with Parkinson’s will gather at Van Andel Research Institute with one goal in mind—finding a cure…

August 3, 2017 Promising results from study of type 2 diabetes drug in treatment of Parkinson’s disease

Evidence continues to mount that a newer class of anti-diabetic drugs called incretin mimetics, or glucagon-like peptide-1 receptor agonists, could slow…

December 30, 2016 What difference does a year make?

When it comes to biomedical research and science education, a year can make all the difference. In 2016, we celebrated Van Andel…

December 7, 2016 Diabetes drug slows experimental Parkinson’s disease progression, human trials to begin next year

New data published today shows drug preserves critical brain function in laboratory models of Parkinson’s GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally…

VAI DEFAULT HEADER
September 8, 2016 Diabetes drug focus of new clinical trial for Parkinson’s disease

HIGHLIGHTS A clinical trial is now underway at Cedars-Sinai in Los Angeles to test the efficacy and safety of a type II diabetes drug as…

VAI DEFAULT HEADER
July 12, 2016 Michael J. Fox Foundation, Van Andel Research Institute and The Cure Parkinson’s Trust collaborate to assess the clinical use and development of nilotinib in Parkinson’s disease

Note: To read the commentary published in the Journal of Parkinson's Disease click here. Investigators will focus on safety for long-term use in non-cancer…